Home
SYRS
SYRS News

Latest Syros Pharmaceuticals Inc. (SYRS) News on November 21, 2024

Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal

Zacks

7 days ago

Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal

Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright

TipRanks

7 days ago

Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright

Syros stock craters after lead cancer therapy flops in Phase III trial

Clinical Trials Arena

8 days ago

Syros stock craters after lead cancer therapy flops in Phase III trial

Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression

Business Wire

9 days ago

Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression

Syros Pharmaceuticals Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023)

Simply Wall St.

19 days ago

Syros Pharmaceuticals Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023)

Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlights: Strategic Focus on ...

GuruFocus.com

20 days ago

Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlights: Strategic Focus on ...

Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update

Business Wire

21 days ago

Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update

Business Wire

a month ago

Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

Syros Pharmaceuticals Inc (SYRS) Q2 2024 Earnings Call Highlights: Strategic Focus on ...

GuruFocus.com

a month ago

Syros Pharmaceuticals Inc (SYRS) Q2 2024 Earnings Call Highlights: Strategic Focus on ...

Insider Spends US$161k Buying More Shares In Syros Pharmaceuticals

Simply Wall St.

2 months ago

Insider Spends US$161k Buying More Shares In Syros Pharmaceuticals

Argus Research

2 months ago

Daily – Vickers Top Buyers & Sellers for 09/13/2024

Insider Buying: CFO Jason Haas Acquires 100,000 Shares of Syros Pharmaceuticals Inc (SYRS)

GuruFocus.com

2 months ago

Insider Buying: CFO Jason Haas Acquires 100,000 Shares of Syros Pharmaceuticals Inc (SYRS)

Insider Buying: President & CEO Conley Chee Acquires Shares of Syros Pharmaceuticals Inc (SYRS)

GuruFocus.com

2 months ago

Insider Buying: President & CEO Conley Chee Acquires Shares of Syros Pharmaceuticals Inc (SYRS)

Business Wire

3 months ago

Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences

Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination

Zacks

3 months ago

Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination

Syros Pharmaceuticals (SYRS) Loses -70.55% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

3 months ago

Syros Pharmaceuticals (SYRS) Loses -70.55% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

MT Newswires

3 months ago

Sector Update: Health Care Stocks Rise Late Afternoon

MT Newswires

3 months ago

Top Midday Decliners

Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome

Benzinga

3 months ago

Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome

Syros’ stock craters after Phase II AML trial termination due to inefficacy

Pharmaceutical Technology

3 months ago

Syros’ stock craters after Phase II AML trial termination due to inefficacy

MT Newswires

3 months ago

Top Premarket Decliners

MT Newswires

3 months ago

Syros Pharmaceuticals Ends Trial of Prospective Acute Myeloid Leukemia Treatment -- Shares Plunge

Business Wire

3 months ago

Syros Provides Update on SELECT-AML-1 Phase 2 Clinical Trial

Does Syros Pharmaceuticals (SYRS) Have the Potential to Rally 251.92% as Wall Street Analysts Expect?

Zacks

4 months ago

Does Syros Pharmaceuticals (SYRS) Have the Potential to Rally 251.92% as Wall Street Analysts Expect?

Business Wire

4 months ago

Syros Reports Second Quarter 2024 Financial Results and Provides a Business Update

Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024

Business Wire

4 months ago

Syros to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024

Syros (SYRS) Stock Rises More Than 35% in 3 Months: Here's Why

Zacks

4 months ago

Syros (SYRS) Stock Rises More Than 35% in 3 Months: Here's Why

Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) high institutional ownership speaks for itself as stock continues to impress, up 17% over last week

Simply Wall St.

5 months ago

Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) high institutional ownership speaks for itself as stock continues to impress, up 17% over last week

Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression

Business Wire

5 months ago

Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression

GuruFocus.com

6 months ago

Syros Pharmaceuticals Inc (SYRS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...

Thomson Reuters StreetEvents

6 months ago

Q1 2024 Syros Pharmaceuticals Inc Earnings Call

Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Business Wire

6 months ago

Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Syros to Participate in Upcoming Investor Conferences

Business Wire

6 months ago

Syros to Participate in Upcoming Investor Conferences

Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024

Business Wire

6 months ago

Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024

Will Femasys Inc. (FEMY) Report Negative Q1 Earnings? What You Should Know

Zacks

7 months ago

Will Femasys Inc. (FEMY) Report Negative Q1 Earnings? What You Should Know

Analysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for

Zacks

7 months ago

Analysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for

The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals

Zacks

7 months ago

The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals

Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML

Zacks

7 months ago

Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML

Syros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock?

Zacks

7 months ago

Syros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock?

Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression

Business Wire

7 months ago

Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

8 months ago

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2023 Earnings Call Transcript

Insider Monkey

8 months ago

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2023 Earnings Call Transcript

Syros Pharmaceuticals Full Year 2023 Earnings: Misses Expectations

Simply Wall St.

8 months ago

Syros Pharmaceuticals Full Year 2023 Earnings: Misses Expectations

Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Business Wire

8 months ago

Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial

Business Wire

8 months ago

Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial

Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024

Business Wire

8 months ago

Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024

Syros to Participate in TD Cowen 44th Annual Health Care Conference

Business Wire

9 months ago

Syros to Participate in TD Cowen 44th Annual Health Care Conference

Investors in Syros Pharmaceuticals (NASDAQ:SYRS) have seen respectable returns of 99% over the past year

Simply Wall St.

9 months ago

Investors in Syros Pharmaceuticals (NASDAQ:SYRS) have seen respectable returns of 99% over the past year

3 Once-in-a-Lifetime Penny Stocks With Unprecedented Surge Potential

InvestorPlace

10 months ago

3 Once-in-a-Lifetime Penny Stocks With Unprecedented Surge Potential

Great Southern Bancorp, Inc. to Hold 35th Annual Meeting of Stockholders

GlobeNewswire

10 months ago

Great Southern Bancorp, Inc. to Hold 35th Annual Meeting of Stockholders

iHeartMedia Announces Jess Hilarious as New Co-host for the Nationally Syndicated Hit Radio Show "The Breakfast Club"

Business Wire

10 months ago

iHeartMedia Announces Jess Hilarious as New Co-host for the Nationally Syndicated Hit Radio Show "The Breakfast Club"

Down -20.21% in 4 Weeks, Here's Why OneWater Marine (ONEW) Looks Ripe for a Turnaround

Zacks

10 months ago

Down -20.21% in 4 Weeks, Here's Why OneWater Marine (ONEW) Looks Ripe for a Turnaround

GuruFocus.com

10 months ago

Heritage Commerce Corp Reports $64.4 Million Full Year Net Income for 2023

KNOT Offshore Partners LP Announces Fourth Quarter 2023 Earnings Results Conference Call

Business Wire

10 months ago

KNOT Offshore Partners LP Announces Fourth Quarter 2023 Earnings Results Conference Call

Thomson Reuters StreetEvents

10 months ago

Q3 2024 Karooooo Ltd Earnings Call

CNB Financial (CCNE) Beats Q4 Earnings and Revenue Estimates

Zacks

10 months ago

CNB Financial (CCNE) Beats Q4 Earnings and Revenue Estimates

Karooooo Demonstrates Its Ability to Grow at Scale, Expand Margins and Deliver Record Earnings

Business Wire

10 months ago

Karooooo Demonstrates Its Ability to Grow at Scale, Expand Margins and Deliver Record Earnings

Virtus Total Return Fund Inc. Discloses Sources of Distribution – Section 19(a) Notice

Business Wire

10 months ago

Virtus Total Return Fund Inc. Discloses Sources of Distribution – Section 19(a) Notice

Oatly Announces Sweet Collaboration with Carvel®, One of America’s Most Beloved Ice Cream Destinations

GlobeNewswire

10 months ago

Oatly Announces Sweet Collaboration with Carvel®, One of America’s Most Beloved Ice Cream Destinations

Syros (SYRS) Stock Surges 200% in 3 Months: Here's Why

Zacks

10 months ago

Syros (SYRS) Stock Surges 200% in 3 Months: Here's Why

RBB Bancorp Declares Quarterly Cash Dividend of $0.16 Per Common Share

Business Wire

10 months ago

RBB Bancorp Declares Quarterly Cash Dividend of $0.16 Per Common Share

Are You Looking for a Top Momentum Pick? Why Syros Pharmaceuticals, Inc. (SYRS) is a Great Choice

Zacks

10 months ago

Are You Looking for a Top Momentum Pick? Why Syros Pharmaceuticals, Inc. (SYRS) is a Great Choice

Syros Pharmaceuticals, Inc. (SYRS) Is a Great Choice for 'Trend' Investors, Here's Why

Zacks

10 months ago

Syros Pharmaceuticals, Inc. (SYRS) Is a Great Choice for 'Trend' Investors, Here's Why

What Makes Syros Pharmaceuticals, Inc. (SYRS) a New Buy Stock

Zacks

10 months ago

What Makes Syros Pharmaceuticals, Inc. (SYRS) a New Buy Stock

Wall Street Analysts Predict a 199.31% Upside in Syros Pharmaceuticals, Inc. (SYRS): Here's What You Should Know

Zacks

10 months ago

Wall Street Analysts Predict a 199.31% Upside in Syros Pharmaceuticals, Inc. (SYRS): Here's What You Should Know

Oatly to Report Fourth Quarter 2023 Financial Results on February 15, 2024

GlobeNewswire

10 months ago

Oatly to Report Fourth Quarter 2023 Financial Results on February 15, 2024

Are You Looking for a Top Momentum Pick? Why Organogenesis (ORGO) is a Great Choice

Zacks

10 months ago

Are You Looking for a Top Momentum Pick? Why Organogenesis (ORGO) is a Great Choice

L.B. Foster's (NASDAQ:FSTR) investors will be pleased with their respectable 93% return over the last year

Simply Wall St.

10 months ago

L.B. Foster's (NASDAQ:FSTR) investors will be pleased with their respectable 93% return over the last year

ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids

GlobeNewswire

10 months ago

ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids

Why Syros Pharmaceuticals (SYRS) Stock Might be a Great Pick

Zacks

10 months ago

Why Syros Pharmaceuticals (SYRS) Stock Might be a Great Pick

Virtus Investment Partners Reports Preliminary December 31, 2023 Assets Under Management

Business Wire

10 months ago

Virtus Investment Partners Reports Preliminary December 31, 2023 Assets Under Management

New EV Frontiers: 3 Stocks Ready to Drive Past Tesla in 2024

InvestorPlace

10 months ago

New EV Frontiers: 3 Stocks Ready to Drive Past Tesla in 2024

Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene

Business Wire

10 months ago

Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene

Amundi US Declares Monthly Distributions for Pioneer Closed-End Funds

Business Wire

a year ago

Amundi US Declares Monthly Distributions for Pioneer Closed-End Funds

Virtus Investment Partners to Transfer Listing of Common Stock to New York Stock Exchange

Business Wire

a year ago

Virtus Investment Partners to Transfer Listing of Common Stock to New York Stock Exchange

Perspective Therapeutics Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer Treatment

GlobeNewswire

a year ago

Perspective Therapeutics Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer Treatment

The Aaron's Company, Inc. (AAN) is Attracting Investor Attention: Here is What You Should Know

Zacks

a year ago

The Aaron's Company, Inc. (AAN) is Attracting Investor Attention: Here is What You Should Know

Himax Teams Up with DESMAN to Unveil Revolutionary High-End Smart Door Locks at CES 2024

GlobeNewswire

a year ago

Himax Teams Up with DESMAN to Unveil Revolutionary High-End Smart Door Locks at CES 2024

Steven Cohen's Point72 Asset Management Acquires New Stake in Syros Pharmaceuticals

GuruFocus.com

a year ago

Steven Cohen's Point72 Asset Management Acquires New Stake in Syros Pharmaceuticals

Absci to Participate in the 26th Annual Needham Growth Conference

GlobeNewswire

a year ago

Absci to Participate in the 26th Annual Needham Growth Conference

12 Best Solar Power Stocks To Invest In According to Financial Media

Insider Monkey

a year ago

12 Best Solar Power Stocks To Invest In According to Financial Media

Sprott (TSE:SII) shareholders have earned a 16% CAGR over the last five years

Simply Wall St.

a year ago

Sprott (TSE:SII) shareholders have earned a 16% CAGR over the last five years

Despite recent sales, Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insiders remain the largest stockholders with 39% ownership

Simply Wall St.

a year ago

Despite recent sales, Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insiders remain the largest stockholders with 39% ownership

Skeena Files Updated Feasibility Study Technical Report for Eskay Creek

ACCESSWIRE

a year ago

Skeena Files Updated Feasibility Study Technical Report for Eskay Creek

Zacks Industry Outlook Highlights Federal Agricultural Mortgage, LendingTree and Ocwen Financial

Zacks

a year ago

Zacks Industry Outlook Highlights Federal Agricultural Mortgage, LendingTree and Ocwen Financial

Limoneira (LMNR) Reports Q4 Loss, Tops Revenue Estimates

Zacks

a year ago

Limoneira (LMNR) Reports Q4 Loss, Tops Revenue Estimates

EMX Announces Early Repayment of the US$10M Sprott Credit Facility

Newsfile

a year ago

EMX Announces Early Repayment of the US$10M Sprott Credit Facility

Nature’s Sunshine Recognized with Best Company Culture Award

GlobeNewswire

a year ago

Nature’s Sunshine Recognized with Best Company Culture Award

VIZSLA SILVER PROVIDES 2023 YEAR-END SUMMARY AND 2024 OUTLOOK

CNW Group

a year ago

VIZSLA SILVER PROVIDES 2023 YEAR-END SUMMARY AND 2024 OUTLOOK

VIZSLA SILVER PUBLISHES INAUGURAL SUSTAINABILITY REPORT

CNW Group

a year ago

VIZSLA SILVER PUBLISHES INAUGURAL SUSTAINABILITY REPORT

With 75% ownership in Celestica Inc. (TSE:CLS), institutional investors have a lot riding on the business

Simply Wall St.

a year ago

With 75% ownership in Celestica Inc. (TSE:CLS), institutional investors have a lot riding on the business

West Virginia governor spars with bank over $300M debt

American Banker

a year ago

West Virginia governor spars with bank over $300M debt

13 Hot Penny Stocks To Buy According to Hedge Funds

Insider Monkey

a year ago

13 Hot Penny Stocks To Buy According to Hedge Funds

US Army Awards Nearly $20 Million Contract Extension to Gilat to Sustain Anytime, Anywhere Satellite Connectivity

GlobeNewswire

a year ago

US Army Awards Nearly $20 Million Contract Extension to Gilat to Sustain Anytime, Anywhere Satellite Connectivity

Orange Bank & Trust Hires Three New Officers to Support Growing Trust Division

ACCESSWIRE

a year ago

Orange Bank & Trust Hires Three New Officers to Support Growing Trust Division

Ethan Allen, The Interior Design Destination, Celebrates Grand Reopenings

GlobeNewswire

a year ago

Ethan Allen, The Interior Design Destination, Celebrates Grand Reopenings

Lyra Therapeutics Insider Ups Holding By 11% During Year

Simply Wall St.

a year ago

Lyra Therapeutics Insider Ups Holding By 11% During Year

Terns Pharmaceuticals Presents Late-Breaking Data from Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH at AASLD The Liver Meeting® 2023

GlobeNewswire

a year ago

Terns Pharmaceuticals Presents Late-Breaking Data from Phase 2a DUET Trial of THR-β Agonist TERN-501 in NASH at AASLD The Liver Meeting® 2023

Newtek Business Services Corp. (NASDAQ:NEWT) Q3 2023 Earnings Call Transcript

Insider Monkey

a year ago

Newtek Business Services Corp. (NASDAQ:NEWT) Q3 2023 Earnings Call Transcript

Associated Press Finance

a year ago

Similarweb: Q3 Earnings Snapshot

Share on Social Networks: